Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, on Daratumumab, Pomalidomide, and Dexamethasone for Multiple Myeloma Treatment

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses what advanced practitioners need to know about phase III findings on subcutaneous daratumumab plus pomalidomide and dexamethasone. Compared to pomalidomide and dexamethasone alone, this combination reduced the risk of disease progression or death by 37% for patients with relapsed or refractory multiple myeloma (Abstract 412).